Ian Read adds a new post to his grow­ing ros­ter of post-Pfiz­er po­si­tions — and this one pays well

Ian Read may have to pick up the pace a bit to meet the swelling num­ber of jobs he’s added to his re­sume since re­cent­ly re­tir­ing from Pfiz­er af­ter a 41-year run that in­clud­ed 9 years at the top.

To­day we learned that Read is tak­ing the chair­man’s spot on the board of tech play­er DXC, a da­ta man­age­ment out­fit that has a big fo­cus on health­care and the life sci­ences in­dus­try. Read is be­ing well paid for his time and at­ten­tion. Their SEC fil­ing notes that the ex-Pfiz­er CEO and chair­man will earn an an­nu­al re­tain­er of $450,000 in stock, pro-rat­ed to his March 16 start date.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER